Does immunointensity account for the differences in prognostic significance of Bcl-2 expression in non-small cell lung cancer?

Pathology and Oncology Research

Volumn 6, Issue 2, 2000, Pages 87-92

  Cox, Giles ^a,b   Walker, Rosemary A ^b   Muller, Salli ^b   Abrams, Keith R ^c   Steward, William P ^a   Jo'byrne, Kenneth ^a  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

^b GLENFIELD HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Apoptosis; Bcl 2; Non small cell lung cancer; Prognosis

Indexed keywords

PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION;

EID: 0033845784     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03032355     Document Type: Article

References (3)

1. Amstad PA, Lik H, Ichimiya M, et al: bcl-2 enhancement of malignant transformation in mouse epidermal JB-6 cells. Mol Carcinogenesis 20:231-239, 1997.
2. Anton RC, Brown RW, Younes M, et al: Absence of prognostic significance of bcl-2 immunopositivity in non-small cell lung cancer: Analysis of 427 cases. Hum Pathol 28:1079-1082, 1997.
3. Apolinario RM, van der Volk P, de Jong JS, et al: Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol 15:2456-2466, 1997.